Clicky

Novan, Inc.(NOVN)

Description: Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.


Keywords: Infectious Diseases Organ Systems Dermatology Acne Stage Pharmaceutical Skin Diseases Acne Vulgaris Chemical Entities Cutaneous Conditions Fungal Infection Fungal Infections Genital Wart External Genital And Perianal Warts Inflammatory Skin Diseases Late Stage Pharmaceutical Treatment Of Inflammatory Skin Diseases

Home Page: www.novan.com

NOVN Technical Analysis

4020 Stirrup Creek Drive
Durham, NC 27703
United States
Phone: 919 485 8080


Officers

Name Title
Ms. Paula Brown Stafford M.P.H. Pres, CEO & Chairwoman
Mr. John M. Gay CPA CFO & Corp. Sec.
Mr. Brian M. Johnson Chief Commercial Officer
Mr. John A. Donofrio Jr. Exec. VP, COO & Pres of EPI Health
Mr. Andrew J. Novak VP of Accounting & Bus. Operations and Chief Accounting Officer
Dr. Carri Geer Ph.D. Sr. VP & CTO
Mr. Cole Ikkala Director of Investor Relations, Communications & Bus. Devel.
Mr. Stanley Hollenbach BS, J.D. Sr. VP of R&D
Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D. Chief Medical Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.1023
Price-to-Sales TTM: 2.2951
IPO Date: 2016-09-21
Fiscal Year End: December
Full Time Employees: 29
Back to stocks